DE3226178A1 - Mittel enthaltend n-acetyl-p-aminophenol und ein antacidum - Google Patents
Mittel enthaltend n-acetyl-p-aminophenol und ein antacidumInfo
- Publication number
- DE3226178A1 DE3226178A1 DE19823226178 DE3226178A DE3226178A1 DE 3226178 A1 DE3226178 A1 DE 3226178A1 DE 19823226178 DE19823226178 DE 19823226178 DE 3226178 A DE3226178 A DE 3226178A DE 3226178 A1 DE3226178 A1 DE 3226178A1
- Authority
- DE
- Germany
- Prior art keywords
- apap
- antacid
- tablet
- dose
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims description 76
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 52
- 229940069428 antacid Drugs 0.000 claims description 38
- 239000003159 antacid agent Substances 0.000 claims description 38
- 230000001458 anti-acid effect Effects 0.000 claims description 31
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 68
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 57
- 239000000203 mixture Substances 0.000 description 17
- 239000010410 layer Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 229920002261 Corn starch Polymers 0.000 description 8
- 239000008120 corn starch Substances 0.000 description 8
- 229940099112 cornstarch Drugs 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 7
- 239000001095 magnesium carbonate Substances 0.000 description 7
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 229960005489 paracetamol Drugs 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- -1 OTC Antacid Chemical class 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037058 blood plasma level Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004049 embossing Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229940060367 inert ingredients Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- UTUUIUQHGDRVPU-UHFFFAOYSA-K aluminum;2-aminoacetate;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Al+3].NCC([O-])=O UTUUIUQHGDRVPU-UHFFFAOYSA-K 0.000 description 1
- KLMDYFUUSKOJAX-UHFFFAOYSA-K aluminum;acetate;dihydroxide Chemical compound CC(=O)O[Al](O)O KLMDYFUUSKOJAX-UHFFFAOYSA-K 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002305 phenylpropanolamine hydrochloride Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940050169 povidone k29-32 Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28256581A | 1981-07-13 | 1981-07-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3226178A1 true DE3226178A1 (de) | 1983-01-20 |
Family
ID=23082085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19823226178 Withdrawn DE3226178A1 (de) | 1981-07-13 | 1982-07-13 | Mittel enthaltend n-acetyl-p-aminophenol und ein antacidum |
Country Status (17)
| Country | Link |
|---|---|
| JP (1) | JPS5823617A (cg-RX-API-DMAC10.html) |
| KR (1) | KR840000234A (cg-RX-API-DMAC10.html) |
| AR (1) | AR228661A1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU8436082A (cg-RX-API-DMAC10.html) |
| BE (1) | BE893827A (cg-RX-API-DMAC10.html) |
| CA (1) | CA1182049A (cg-RX-API-DMAC10.html) |
| DE (1) | DE3226178A1 (cg-RX-API-DMAC10.html) |
| DK (1) | DK309282A (cg-RX-API-DMAC10.html) |
| FR (1) | FR2509174A1 (cg-RX-API-DMAC10.html) |
| GB (1) | GB2103087A (cg-RX-API-DMAC10.html) |
| GR (1) | GR76197B (cg-RX-API-DMAC10.html) |
| IT (1) | IT1148199B (cg-RX-API-DMAC10.html) |
| NL (1) | NL8202773A (cg-RX-API-DMAC10.html) |
| NO (1) | NO822385L (cg-RX-API-DMAC10.html) |
| PT (1) | PT75234B (cg-RX-API-DMAC10.html) |
| SE (1) | SE8204288L (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA823760B (cg-RX-API-DMAC10.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19502789A1 (de) * | 1995-01-28 | 1996-08-01 | Dirk Krischenowski | Arzneimittel |
| DE102004042139B4 (de) * | 2004-08-31 | 2009-06-10 | Aristocon Verwaltungs- Gmbh | Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1732939A (zh) * | 1994-09-02 | 2006-02-15 | 弗吉尼亚州立大学 | 含非麻醉止痛药和止痛增效剂的解痛组合物 |
| US6048540A (en) * | 1997-01-29 | 2000-04-11 | Chong Kun Dang Corp. | Acetamenophen composition with reduced liver toxicity |
| GB9704524D0 (en) | 1997-03-05 | 1997-04-23 | Smithkline Beecham Plc | Composition |
| GB0114069D0 (en) | 2001-06-08 | 2001-08-01 | Smithkline Beecham Plc | Composition |
| US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| PE20061125A1 (es) * | 2004-10-28 | 2006-11-08 | Novartis Ag | Composicion farmaceutica que comprende acetaminofen, cafeina y opcionalmente aspirina junto a un agente alcalino |
| JP2009517346A (ja) | 2005-11-28 | 2009-04-30 | イメイジノット ピーティーワイ エルティーディー | 治療用化合物の経口送達系 |
| GB0607085D0 (en) | 2006-04-07 | 2006-05-17 | Smithkline Beecham Corp | Novel compositions |
| GB0813929D0 (en) * | 2008-07-30 | 2008-09-03 | Glaxo Group Ltd | Novel method |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1241201A (en) * | 1968-07-23 | 1971-08-04 | Sterling Winthrop Group Ltd | Improvements in or relating to effervescent pharmaceutical compositions |
| GB1221038A (en) * | 1969-09-18 | 1971-02-03 | H & T Kirby & Company Ltd | Improvements in effervescent tablet compositions |
| GB1359614A (en) * | 1971-04-06 | 1974-07-10 | Dev Et De Rech Soc Fr De | Method for the manufacture of effervescent tablets |
-
1981
- 1981-10-22 CA CA000388485A patent/CA1182049A/en not_active Expired
-
1982
- 1982-05-28 ZA ZA823760A patent/ZA823760B/xx unknown
- 1982-06-01 AU AU84360/82A patent/AU8436082A/en not_active Abandoned
- 1982-06-07 AR AR289615A patent/AR228661A1/es active
- 1982-06-11 GR GR68411A patent/GR76197B/el unknown
- 1982-06-23 FR FR8210959A patent/FR2509174A1/fr active Pending
- 1982-07-08 NL NL8202773A patent/NL8202773A/nl not_active Application Discontinuation
- 1982-07-09 JP JP57118729A patent/JPS5823617A/ja active Pending
- 1982-07-09 IT IT48788/82A patent/IT1148199B/it active
- 1982-07-09 DK DK309282A patent/DK309282A/da not_active Application Discontinuation
- 1982-07-09 NO NO822385A patent/NO822385L/no unknown
- 1982-07-12 PT PT75234A patent/PT75234B/pt unknown
- 1982-07-12 GB GB08220223A patent/GB2103087A/en not_active Withdrawn
- 1982-07-12 SE SE8204288A patent/SE8204288L/xx not_active Application Discontinuation
- 1982-07-12 BE BE0/208579A patent/BE893827A/fr not_active IP Right Cessation
- 1982-07-13 DE DE19823226178 patent/DE3226178A1/de not_active Withdrawn
- 1982-07-13 KR KR1019820003123A patent/KR840000234A/ko not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19502789A1 (de) * | 1995-01-28 | 1996-08-01 | Dirk Krischenowski | Arzneimittel |
| DE102004042139B4 (de) * | 2004-08-31 | 2009-06-10 | Aristocon Verwaltungs- Gmbh | Perorale Darreichungsformen zur Erzielung eines Retardierungseffektes nach der Arzneimitteleinnahme mit einer Mahlzeit |
Also Published As
| Publication number | Publication date |
|---|---|
| SE8204288L (sv) | 1983-01-14 |
| ZA823760B (en) | 1983-03-30 |
| GB2103087A (en) | 1983-02-16 |
| IT8248788A0 (it) | 1982-07-09 |
| CA1182049A (en) | 1985-02-05 |
| AU8436082A (en) | 1983-01-20 |
| IT1148199B (it) | 1986-11-26 |
| FR2509174A1 (fr) | 1983-01-14 |
| KR840000234A (ko) | 1984-02-18 |
| BE893827A (fr) | 1983-01-12 |
| NO822385L (no) | 1983-01-14 |
| SE8204288D0 (sv) | 1982-07-12 |
| NL8202773A (nl) | 1983-02-01 |
| PT75234A (en) | 1982-08-01 |
| AR228661A1 (es) | 1983-03-30 |
| DK309282A (da) | 1983-01-14 |
| PT75234B (en) | 1985-10-04 |
| JPS5823617A (ja) | 1983-02-12 |
| GR76197B (cg-RX-API-DMAC10.html) | 1984-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69004708T2 (de) | Tablette mit Doppelwirkung. | |
| DE69826290T2 (de) | Pharmazeutische zusammensetzungen zur kontrollierten freigabe von wirkstoffen | |
| DE3329265C2 (cg-RX-API-DMAC10.html) | ||
| DE3246492C2 (de) | Verfahren zur Herstellung therapeutischer Präparate auf der Basis von Hydroxypropylmethylzellulose mit verlängertem Freisetzungsverlauf | |
| DE69022876T2 (de) | Arzneimittelformulierungen mit verzögerter Wirkstoffabgabe. | |
| EP0682945B1 (de) | Orale Retard-Präparation | |
| DE3879080T2 (de) | Pharmazeutische matrix mit verzoegerter freisetzung und verfahren. | |
| DE69313983T2 (de) | Ein Guanidinothiazol und Antazida enthaltende Arzneimittel | |
| DE3783394T2 (de) | Arzneizubereitung zur oralen anwendung. | |
| DE69629797T2 (de) | Matrix zur gesteuerten freisetzung von arzneistoffen | |
| DE69000881T2 (de) | 2-propylvaleriansaeure enthaltende arzneizubereitung mit verzoegerter wirkstofffreigabe. | |
| DE69530759T2 (de) | Filmbeschichtete tablette, die paracetamol und domperidone enthält | |
| EP0857064B1 (de) | Stabilisierte schilddrüsenhormonhaltige arzneimittel | |
| DE68903605T2 (de) | Kautablette. | |
| DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
| DE2907215A1 (de) | Feste depotarzneimittelpraeparate und verfahren zu deren herstellung | |
| CH646331A5 (de) | Dosiseinheit in form einer pharmazeutisch aktives material enthaltenden kapsel. | |
| DE60203537T2 (de) | 5ht1-rezeptoragonist enthaltendes arzneimittel | |
| DE3719818C2 (de) | Pharmazeutische Zusammensetzung | |
| DE69111574T2 (de) | Polycarbophil-Kalzium enthaltendes Arzneimittel. | |
| DE60225686T2 (de) | Paracetamol enthaltende tablette | |
| DE3226178A1 (de) | Mittel enthaltend n-acetyl-p-aminophenol und ein antacidum | |
| DE69101111T2 (de) | Oral anzuwendende Arzneimittel in Einzeldosisform. | |
| DE3882765T2 (de) | Tabletten mit verzögerter Freisetzung auf der Basis von hochmolekularer Hydroxypropylmethylcellulose und Verfahren zu ihrer Herstellung. | |
| DE3733540A1 (de) | Eine pharmazeutische zusammensetzung mit verzoegerter freigabe des wirkstoffes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |